

FIG. 1

# ANTI-CD40L mAb TREATMENT OF DONOR T CELLS IN A PRIMARY MLR CULTURE




FIG. 2A

THE ADDITION OF ANTI-CD40L mAb INHIBITS IL-2 PRODUCTION IN PRIMARY MLR CULTURE




FIG. 2A

FIG. 2B

THE ADDITION OF ANTI-CD40L mAb LEADS TO A REDUCTION IN  
INTERFERON GAMMA PRODUCTION




FIG. 2B

FIG. 3A

ANTI-CD40L mAb INDUCED ANTI-HOST ALLOANTIGEN HYPORESPONSIVENESS




FIG. 3A

DAYS OF SECONDARY MLR CULTURE

FIG. 3B

DONOR T CELLS EXPOSED TO ANTI-CD40L mAb IN PRIMARY MLR CULTURE




FIG. 3B

DAYS OF SECONDARY MLR CULTURE

TOP SECRET

THE ADDITION OF ANTI-CD40L mAb TO A PRIMARY MLR CULTURE INHIBITS IL-2 PRODUCTION




FIG. 4A

FIG. 4B

THE ADDITION OF ANTI-CD40L mAb TO A PRIMARY MLR CULTURE INHIBITS INTERFERON GAMMA PRODUCTION




FIG. 4B

TOP SECRET 860

ANTI-CD40L mAb TREATMENT OF DONOR T CELLS IN AN MLR CULTURE  
 REDUCES IN VIVO GVHD CAPACITY





FIG. 5A



FOET 92T5E860



**FIG. 5B**